Published in Antimicrob Agents Chemother on February 01, 1996
Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother (2001) 3.62
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother (1998) 2.59
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother (1999) 1.99
Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis (2005) 1.83
Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother (2001) 1.38
Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility. Emerg Infect Dis (2005) 1.32
Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital. Emerg Infect Dis (2001) 1.19
Genotypic analysis of Escherichia coli strains from poultry carcasses and their susceptibilities to antimicrobial agents. Appl Environ Microbiol (2001) 0.96
Multicenter comparison of three different analytical systems for evaluation of DNA banding patterns from Cryptococcus neoformans. J Clin Microbiol (2002) 0.87
The effect of a hospital-wide urine culture screening intervention on the incidence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species. Infect Control Hosp Epidemiol (2013) 0.79
Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions. Infect Control Hosp Epidemiol (2012) 0.75
Resistance Pattern and Molecular Characterization of Enterotoxigenic Escherichia coli (ETEC) Strains Isolated in Bangladesh. PLoS One (2016) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J Infect Dis (1990) 8.33
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
DNA fingerprinting of medically important microorganisms by use of PCR. Clin Microbiol Rev (1994) 4.86
4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother (1991) 4.35
DNA fingerprinting of Escherichia coli O157:H7 strains by pulsed-field gel electrophoresis. J Clin Microbiol (1992) 4.24
RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains. Nucleic Acids Res (1993) 3.10
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother (1994) 2.87
Concordant clonal delineation of methicillin-resistant Staphylococcus aureus by macrorestriction analysis and polymerase chain reaction genome fingerprinting. J Clin Microbiol (1993) 2.79
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1993) 2.68
Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa. J Clin Microbiol (1995) 2.43
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother (1994) 2.24
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1988) 1.88
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med (1994) 1.81
Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother (1995) 1.78
Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother (1990) 1.75
Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother (1995) 1.72
Pulsed-field gel electrophoresis of genomic restriction fragments as a tool for the epidemiological analysis of Staphylococcus aureus and coagulase-negative staphylococci. FEMS Microbiol Lett (1992) 1.67
Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward. J Antimicrob Chemother (1995) 1.57
Physical genome analysis of bacteria. Electrophoresis (1993) 1.56
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother (1994) 1.49
Arbitrarily primed PCR DNA fingerprinting of Escherichia coli O157:H7 strains by using templates from boiled cultures. J Clin Microbiol (1995) 1.31
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection (1994) 1.31
Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis (1994) 1.29
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis (1995) 1.27
International inter- and intrahospital patient spread of a multiple antibiotic-resistant strain of Klebsiella pneumoniae. J Infect Dis (1995) 0.99
Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother (1994) 0.97
The epidemiology of bacterial resistance to quinolones. Drugs (1993) 0.85
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44
New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. Antimicrob Agents Chemother (1989) 5.49
Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of bacterial strains routinely isolated in a clinical microbiology laboratory. J Clin Microbiol (2010) 5.25
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (1997) 5.22
Genetic characterization of clones of the bacterium Listeria monocytogenes causing epidemic disease. Proc Natl Acad Sci U S A (1989) 5.00
Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother (1998) 4.93
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother (1996) 4.24
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
Evaluation of a lysis-centrifugation system for recovery of yeasts and filamentous fungi from blood. J Clin Microbiol (1983) 3.79
CD14 is a pattern recognition receptor. Immunity (1994) 3.79
Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A (1976) 3.58
Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol (1997) 3.54
Deletions of chromosomal regions coding for fimbriae and hemolysins occur in vitro and in vivo in various extraintestinal Escherichia coli isolates. Microb Pathog (1990) 3.18
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2002) 3.10
Evaluation of MRSA-Screen, a simple anti-PBP 2a slide latex agglutination kit, for rapid detection of methicillin resistance in Staphylococcus aureus. J Clin Microbiol (1999) 2.94
Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun (1994) 2.92
The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother (1999) 2.87
A large plasmid from Halobacterium halobium carrying genetic information for gas vacuole formation. Plasmid (1979) 2.79
Natural history of aortic valve endocarditis in rats. Infect Immun (1982) 2.74
Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun (1992) 2.69
Matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative to 16S rRNA gene sequencing for identification of difficult-to-identify bacterial strains. J Clin Microbiol (2010) 2.69
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother (1998) 2.59
Detection of legionellae in hospital water samples by quantitative real-time LightCycler PCR. Appl Environ Microbiol (2001) 2.43
Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. J Clin Microbiol (1995) 2.41
Comparison of PCR-based DNA fingerprinting techniques for the identification of Listeria species and their use for atypical Listeria isolates. Int J Syst Bacteriol (1998) 2.40
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother (2000) 2.40
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis (1983) 2.35
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med (1999) 2.35
Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology (1994) 2.35
Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis (1993) 2.35
Prospective, randomised, double blind trial of prophylaxis with single dose of co-amoxiclav before percutaneous endoscopic gastrostomy. BMJ (1999) 2.28
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 2.27
Retrospective comparison of three blood culture media for the recovery of yeasts from clinical specimens. Eur J Clin Microbiol (1983) 2.15
Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P-450 lanosterol-alpha-demethylase (L1A1) gene fragment. J Clin Microbiol (1994) 2.15
Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother (2001) 2.14
Ochrobactrum anthropi bacteremia: report of four cases and short review. Infection (1994) 2.13
Structure and structure formation of viroids. J Mol Biol (1979) 2.03
A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group. Diagn Microbiol Infect Dis (2000) 1.99
Clinical evaluation of the lysis-centrifugation blood culture system for the detection of fungemia and comparison with a conventional biphasic broth blood culture system. J Clin Microbiol (1984) 1.97
Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J (2008) 1.97
Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone. Antimicrob Agents Chemother (2001) 1.93
Pulsed field electrophoresis of genomic restriction fragments for the detection of nosocomial Legionella pneumophila in hospital water supplies. J Clin Microbiol (1991) 1.89
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother (2002) 1.88
Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis (2005) 1.83
Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol (1992) 1.82
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med (1994) 1.81
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut (1996) 1.72
A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology (2000) 1.71
Trends in antibiotic use at a university hospital: defined or prescribed daily doses? Patient days or admissions as denominator? Infection (2006) 1.66
Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis (1989) 1.64
Characterization by DNA restriction endonuclease analysis of Listeria monocytogenes strains related to the Swiss epidemic of listeriosis. J Clin Microbiol (1990) 1.64
Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother (1995) 1.63
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother (2000) 1.61
CRB-65 predicts death from community-acquired pneumonia. J Intern Med (2006) 1.61
Typing of Pneumocystis carinii f. sp. hominis by single-strand conformation polymorphism of four genomic regions. J Clin Microbiol (1997) 1.59
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.58
Infection of Acanthamoeba castellanii by Chlamydia pneumoniae. Appl Environ Microbiol (1997) 1.55
Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS (1994) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother (2003) 1.55
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J (2009) 1.54
Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis within human macrophages and suppresses respiratory burst. Infect Immun (2000) 1.53
Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet (1989) 1.53
Detection of yeasts and filamentous fungi in blood cultures during a 10-year period (1972 to 1981). J Clin Microbiol (1982) 1.52
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol (1994) 1.51
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis (1991) 1.50
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother (1990) 1.49
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother (1994) 1.49
gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother (1996) 1.48
Structural and biological properties of mycoplasmavirus MVL3: an unusual virus-procaryote interaction. J Virol (1979) 1.48
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Staphylococcus saprophyticus urease: characterization and contribution to uropathogenicity in unobstructed urinary tract infection of rats. Infect Immun (1989) 1.47
Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Chemother (1998) 1.47
Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 1.47
Altered sphingomyelinase and ceramide expression in the setting of ischemic and nephrotoxic acute renal failure. Kidney Int (1998) 1.47